Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 20.99
- Piotroski Score 4.00
- Grade Buy
- Symbol (CRVO)
- Company CervoMed Inc.
- Price $14.53
- Changes Percentage (-0.48%)
- Change -$0.07
- Day Low $13.50
- Day High $14.89
- Year High $26.38
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/10/2024
- Fiscal Year End N/A
- Average Stock Price Target $55.00
- High Stock Price Target $65.00
- Low Stock Price Target $55.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.20
- Trailing P/E Ratio -95.95
- Forward P/E Ratio -95.95
- P/E Growth -95.95
- Net Income $-2,171,873
Income Statement
Quarterly
Annual
Latest News of CRVO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
CervoMed Inc. (CRVO) Stock Price, News, Quote & History
CervoMed Inc. is a biotech firm focused on developing treatments for age-related neurologic disorders, with a lead drug candidate, neflamapimod, targeting various conditions like DLB and Alzheimer's. ...
By Yahoo! Finance | 1 month ago -
CervoMed (NASDAQ:CRVO) Is In A Good Position To Deliver On Growth Plans
Investors are drawn to unprofitable companies like CervoMed due to potential success. Despite high cash burn, CervoMed's revenue growth is promising. With a cash runway of 10 months, the company may n...
By Yahoo! Finance | 3 months ago